A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia.

Trial Profile

A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Cariprazine (Primary) ; Aripiprazole
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 20 Sep 2016 Post hoc pooled analysis results of this (NCT01104766) and other trials (NCT01058096, NCT00488618, NCT00404573, NCT01058668, NCT01104779, NCT00694707) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
    • 20 Sep 2016 Post hoc pooled analysis results of this (NCT01104766) and other trial (NCT00694707) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
    • 20 Sep 2016 Results of a post-hoc analysis,presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top